{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-058594","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.343974+00:00","generated_at":"2026-05-16T12:24:07.219862+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vistagen's PALISADE-3 Phase 3 study of fasedienol fails primary endpoint in social anxiety disorder","bullets":["LS mean change from baseline on SUDS score: fasedienol 13.6 (SE 1.54) vs placebo 14.0 (SE 1.51); no statistical significance.","Secondary endpoints also showed no treatment difference between fasedienol and placebo.","Favorable safety data consistent with prior trials; no new safety signals.","Phase 3 failure likely halts development path for intranasal fasedienol in acute social anxiety."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-058594","json":"https://secwatch.observer/filing/0001628280-25-058594.json","markdown":"https://secwatch.observer/filing/0001628280-25-058594.md","text":"https://secwatch.observer/filing/0001628280-25-058594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/0001628280-25-058594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/vtgn-20251217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:24:07.219862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}